Seer Enters into a Co-Marketing and Sales Agreement with Thermo Fisher Scientific
November 06 2024 - 4:03PM
Seer, Inc. (Nasdaq: SEER), a leading life sciences company
commercializing a disruptive new platform for proteomics, today
announced a co-marketing and sales agreement with Thermo Fisher
Scientific, the world leader in serving science, to jointly promote
Seer’s Proteograph™ Product Suite alongside Thermo Scientific
Orbitrap Astral™ mass spectrometers. This strategic collaboration
aims to accelerate the adoption of innovative proteomic
technologies, offering researchers an integrated solution for deep,
rapid, and unbiased proteomic analysis at scale.
Under this non-exclusive agreement, Thermo Fisher’s global sales
force will have the ability to quote and sell Seer’s Proteograph
Product Suite, which includes an automation instrument, proprietary
engineered nanoparticles, and software analysis suite, enhancing
the accessibility of this innovative technology to life science
researchers worldwide. The integration is set to commence in early
2025, further expanding the reach of Seer’s platform. The
collaboration will also enable Seer and Thermo Fisher to conduct
joint marketing activities, including conference promotions,
seminars, and webinars, to showcase the combined power of their
proteomic platforms.
“This collaboration represents a pivotal step in our mission to
transform proteomics by integrating our Proteograph Product Suite
with Thermo Fisher’s Orbitrap Astral mass spectrometers,” said Omid
Farokhzad, CEO and Chair of Seer. “Thermo Fisher mass spectrometers
set the gold standard for proteomics. By enabling Thermo Fisher
customers to acquire the Proteograph Product Suite in conjunction
with an Orbitrap Astral, we are expanding access to these powerful
tools and setting a new standard in proteomics that has the
potential to accelerate scientific discoveries and ultimately
improve human health.”
The companies will work together to improve workflows, creating
a seamless sample-to-data experience that integrates the
Proteograph and Astral technologies. The combination of the
Proteograph Product Suite and Orbitrap Astral has generated
exciting data for academic and commercial customers. Seer and
Thermo Fisher plan to collaborate on additional joint research
studies, including population scale studies, to demonstrate the
comprehensive capabilities of their combined platforms, further
solidifying their commitment to advancing the field of
proteomics.
“This agreement builds on our existing partnership with Seer and
represents a strong advancement in accelerating innovation in
proteomics,” said John Lesica, President, Chromatography and Mass
Spectrometry, Thermo Fisher Scientific. “By aligning our
technologies, we are providing our customers with a scalable
end-to-end solution to enable comprehensive proteomic insights,
ultimately driving breakthroughs in understanding human biology and
disease.”
About SeerSeer is a life sciences company
developing transformative products that open a new gateway to the
proteome. Seer’s Proteograph Product Suite is an integrated
solution that includes proprietary engineered nanoparticles,
consumables, automation instrumentation and software to perform
deep, unbiased proteomic analysis at scale in a matter of hours.
Seer designed the Proteograph workflow to be efficient and easy to
use, leveraging widely adopted laboratory instrumentation to
provide a decentralized solution that can be incorporated by nearly
any lab. Seer’s Proteograph Product Suite is for research use only
and is not intended for diagnostic procedures. For more
information, please visit www.seer.bio.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended. Such forward-looking statements are based on
Seer’s beliefs and assumptions and on information currently
available to it on the date of this press release. Forward-looking
statements may involve known and unknown risks, uncertainties and
other factors that may cause Seer’s actual results, performance, or
achievements to be materially different from those expressed or
implied by the forward-looking statements. These statements include
but are not limited to statements regarding the adoption of Seer’s
products and the benefits of the collaboration. These and other
risks are described more fully in Seer’s filings with the
Securities and Exchange Commission (“SEC”) and other documents that
Seer subsequently files with the SEC from time to time. Except to
the extent required by law, Seer undertakes no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
Seer Media Inquiries: Patrick
Schmidtpr@seer.bio
Investor Contact:Carrie
Mendivilinvestor@seer.bio
Seer (NASDAQ:SEER)
Historical Stock Chart
From Nov 2024 to Dec 2024
Seer (NASDAQ:SEER)
Historical Stock Chart
From Dec 2023 to Dec 2024